Literature DB >> 22520355

Ataxia-telangiectasia presenting with a novel immunodeficiency.

Sébastien Perreault1, Geneviève Bernard, Anne Lortie, Françoise Le Deist, Hélène Decaluwe.   

Abstract

Ataxia-telangiectasia is a rare autosomal recessive disorder characterized by progressive cerebellar ataxia, oculocutaneous telangiectasias, and variable degrees of immunodeficiency. Immunologic evaluations of affected patients often reveal anomalies of humoral and cell-mediated immunity. We describe a case of ataxia-telangiectasia with an atypical immunodeficiency and a novel mutation in the ATM gene. The patient presented at age 3 years with a perineal cellulitis associated with profound neutropenia and T-cell lymphopenia. Serum immunoglobulin levels and antibody titers were normal. Neurologic evaluation revealed minimal hypotonia and wide-based gait, without other signs of cerebellar dysfunction. The alpha-fetoprotein level was elevated, and molecular genetic testing confirmed the diagnosis of ataxia-telangiectasia, uncovering a novel ATM gene mutation c.3931C>T (p.Gln1311X) in exon 28. This patient presents a unique immunologic pattern with normal immunoglobulin levels, significant lymphopenia, and profound neutropenia. The diagnosis of ataxia-telangiectasia should be considered in children presenting with gait disorder and immunologic defects, regardless of subtype and severity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22520355     DOI: 10.1016/j.pediatrneurol.2012.02.027

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  7 in total

1.  A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside.

Authors:  Ahmed Aziz Bousfiha; Leïla Jeddane; Fatima Ailal; Waleed Al Herz; Mary Ellen Conley; Charlotte Cunningham-Rundles; Amos Etzioni; Alain Fischer; Jose Luis Franco; Raif S Geha; Lennart Hammarström; Shigeaki Nonoyama; Hans D Ochs; Chaim M Roifman; Reinhard Seger; Mimi L K Tang; Jennifer M Puck; Helen Chapel; Luigi D Notarangelo; Jean-Laurent Casanova
Journal:  J Clin Immunol       Date:  2013-05-09       Impact factor: 8.317

2.  Molecular defects in Moroccan patients with ataxia-telangiectasia.

Authors:  L Jeddane; F Ailal; C Dubois-d'Enghien; O Abidi; I Benhsaien; A Kili; S Chaouki; Y Kriouile; N El Hafidi; H Fadil; R Abilkassem; N Rada; A A Bousfiha; A Barakat; D Stoppa-Lyonnet; H Bellaoui
Journal:  Neuromolecular Med       Date:  2013-01-16       Impact factor: 3.843

3.  The antimicrobial propeptide hCAP-18 plasma levels in neutropenia of various aetiologies: a prospective study.

Authors:  Ying Ye; Göran Carlsson; Jenny M T Karlsson-Sjöberg; Niels Borregaard; Thomas U Modéer; Mats L Andersson; Katrin L-A Pütsep
Journal:  Sci Rep       Date:  2015-06-29       Impact factor: 4.379

4.  Individual Cytokines Modulate the Neurological Symptoms of ATM Deficiency in a Region Specific Manner

Authors:  Chin Wai Hui; Karl Herrup
Journal:  eNeuro       Date:  2015-08-18

5.  A precocious cerebellar ataxia and frequent Fever episodes in a 16-month-old infant revealing ataxia-telangiectasia syndrome.

Authors:  Luigi Nespoli; Annapia Verri; Silvia Tajè; Francesco Paolo Pellegrini; Maddalena Marinoni
Journal:  Case Reports Immunol       Date:  2013-10-28

6.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

Review 7.  Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders.

Authors:  Agata Pastorczak; Andishe Attarbaschi; Simon Bomken; Arndt Borkhardt; Jutte van der Werff Ten Bosch; Sarah Elitzur; Andrew R Gennery; Eva Hlavackova; Arpád Kerekes; Zdenka Křenová; Wojciech Mlynarski; Tomasz Szczepanski; Tessa Wassenberg; Jan Loeffen
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.